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Thiazolidinediones (TZDs), synthetic ligands of perox-
isome proliferator–activated receptor (PPAR)-, are
known to decrease hepatic glucose production and in-
crease glycogen synthesis in diabetic animals. Recently
it was reported that glucokinase (GK) expression was
increased by TZDs in the liver of diabetic ZDF rats.
However, the mechanism whereby TZDs increase GK
expression is not yet studied. We have assumed that
liver type glucokinase (LGK) induction by TZDs could
be achieved by direct transcriptional activation. Thus,
we have dissected the LGK promoter to explore the
presence of a PPAR response element (PPRE) in the
promoter. From this study, we were able to localize a
PPRE in the 116/104 region of the rat LGK gene. The
PPAR-/retinoid X receptor- heterodimer was bound
to the element and activated the LGK promoter. The
LGK promoter lacking the PPRE or having mutations in
the PPRE could not be activated by PPAR-. Further-
more, troglitazone increased endogenous GK mRNA in
primary hepatocytes. These results indicate that
PPAR- can directly activate GK expression in liver and
may contribute to improving glucose homeostasis in
type 2 diabetes. Diabetes 53 (Suppl. 1):S66–S70, 2004
T
he regulation of hepatic glucose metabolism is
important in glucose homeostasis because the
liver stores or produces glucose depending on
metabolic needs. Enzymes involved in the major
metabolic pathways in liver are largely regulated by glu-
cose or its metabolites at transcriptional levels and are
known to contain carbohydrate response elements in their
promoters (1). Although the mechanism whereby glucose
affects the transcription of these genes is not well under-
stood, it is evident that glucokinase (GK) enables glucose
to regulate the expression of glucose-responsive genes (1).
GK functions as a glucose sensor in pancreatic -cells,
hepatocytes, enterocytes, and specialized hypothalamic
neurons (2). GK has been thought to be essential for liver
in maintaining metabolic function because it exerts a
strong influence on glucose utilization by stimulating
glycolysis and glycogen synthesis in liver. Thus, even a
small change in GK expression can lead to a measurable
impact on the blood glucose concentration (3,4).
GK is acutely regulated by the GK regulatory protein
(GKRP), which is mainly localized in the nucleus (5). At
low glucose concentrations, GKRP is associated with GK
in the nucleus. Acute glucose challenge induces dissocia-
tion of the GK-GKRP complex, and then GK is translocated
into cytoplasm, resulting in increased GK activity (6,7).
However, the long-term role of GKRP is thought to be a GK
stabilizer because GKRP knockout mice showed de-
creased GK activity and GK protein level (8,9). Another
mechanism for controlling GK activity involves transcrip-
tion and/or translation levels. The GK gene contains two
distinctive promoters, initially believed to be specific for
pancreatic -cells and hepatocytes, but used to explain
differential expression in the variety of cells where GK is
expressed (10). Of these two promoters, the downstream
promoter regulates liver type GK (LGK) expression.
Peroxisome proliferator–activated receptor (PPAR)- is
a member of the nuclear hormone receptor that contains
the ligand-dependent activation domain (AF-2) (11). Upon
ligand binding, PPAR- heterodimerizes with retinoid X
receptor (RXR)-, binds to the PPAR response element
(PPRE), and activates target gene transcription. Thiazo-
lidinediones (TZDs) are a class of antidiabetic agents that
improve insulin sensitivity in various animal models of
diabetes (12–14). Patients with a dominant-negative muta-
tion in the PPAR- gene show severe hyperglycemia,
which provides a genetic link between PPAR- and type 2
diabetes (15). In liver, TZDs increase glucose utilization
and decrease glucose production, but the mechanism
whereby TZDs affect hepatic glucose metabolism is not yet
clear. Thus, we have assumed that PPAR- can activate the
genes of the glucose-sensing apparatus in the liver.
In this study, we identified a PPRE in the LGK promoter
and demonstrated that TZDs induced LGK expression in
primary hepatocytes. The presence of this functional
PPRE in the promoter suggested that LGK could be a
direct target of PPAR-.
RESEARCH DESIGN AND METHODS
Materials. Troglitazone and expression plasmids pCMX-mPPAR- and
pCMX-mRXR- were described earlier (16). The rat LGK promoter-reporter
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construct pRGL-1448 was described by Kim et al. (17). 5 Serial deletion of
LGK promoter reporter constructs pRGL-238, pRGL-120, and pRGL-76 were
constructed by amplifying rat LGK promoter regions of 238/127, 120/
127, and 76/127, respectively, and subcloning into the pGL3 basic vector.
For construction of truncated promoter reporter constructs pRGLt-120/-77
and pRGLt-89/-63, KpnI sites were introduced into the appropriate region by
site-directed mutagenesis and KpnI-digested fragments were excised out.
Mutant constructs pRGL-120M1, pRGL-120M2, and pRGL-120M3 were pro-
duced by introducing substitution mutations into pRGL-238 using the Quick-
Change site-directed mutagenesis kit (Stratagene, La Jolla, CA). DNA
sequences of all constructs were confirmed by T7 DNA sequencing. The
primers used in site-directed mutagenesis were also used as probes in the
electrophoretic mobility shift assay (EMSA).
Cell culture and transient transfection. Alexander cells were maintained
as described earlier (18). Transient transfections were performed using the
Lipofectamine Plus reagent (Life Technologies, Gaithersburg, MD) according
to the manufacturer’s protocol, and the luciferase assay was performed as
described previously (16).
In vitro transcription and translation. In vitro translated PPAR- and
RXR- were produced using TNT Quick Coupled Transcription/Translation
systems (Promega, Madison, WI) following the manufacturer’s protocol (17).
EMSA. EMSA was performed as described earlier (17). The oligonucleotides
used in EMSA were as follows: RGL-120/-77, 5- CCCTGTCCCTGTGGCCTTT
GTCAAACCCGACCCCACGTGGTTCTTTGTCCTGGC-3; RGL-120/-77M1, 5-
CCCTcTagaTGTGGCCTTTGTCAAACCCGACCCCACGTGGTTCTTTGTCCT
GGC-3; RGL-120/-77M2, 5- CCCTGTCCCTGTctagaTGTCAAACCCGACCC
CACGTGGTTCTTTGTCCTGGC 3; RGL-120/-77M3, 5- CCCTGTCCCTGT
GGCCTTcTagAACCCGACCCCACGTGGTTCTTTGTCCTGGC-3. The PPRE
sequence is underlined, and mutated bases are shown in lowercase letters
(19).
RNA preparation and Northern blot analysis. Total RNA was isolated
from primary hepatocytes using the TRIzol reagent following the manufactur-
er’s protocol (Life Technologies). Total RNA (20 g) was separated on 1%
agarose gels containing 0.66 mol/l formaldehyde. After electrophoresis, RNA
was transferred to a nylon membrane by capillary transfer in the presence of
20  sodium chloride–sodium citrate (SSC). Then the membrane, which was
ultraviolet–cross-linked, was hybridized with 32P-labeled GK or -actin cDNA
probes in Rapid-hyb buffer (Amersham Pharmacia, Buckinghamshire, U.K.) at
65°C for 4 h. After hybridization, the membrane was rinsed with 2 SSC, 0.1%
SDS, followed by 0.2 SSC, 0.1% SDS, and exposed to X-ray film at 70°C
with an intensifying screen.
Statistical analysis. All transfection studies were performed in triplicate and
repeated more than three times. The data were represented as means 	 SD.
Statistical analysis was carried out using Excel software (Microsoft, Red-
mond, WA).
RESULTS
Troglitazone can increase GK expression in primary
hepatocytes. To test whether PPAR- agonists can di-
rectly activate GK gene expression in an isolated system,
we treated troglitazone with primary hepatocytes isolated
from male Sprague-Dawley rats (200–250 g) and measured
the mRNA levels by Northern blot analysis. The transcrip-
tion of the GK gene was increased by troglitazone (Fig. 1).
This result supports the observation that TZDs increase
GK expression in the liver of diabetic ZDF rats (20) and
suggests the presence of PPRE in the LGK promoter.
Localization of PPRE in the LGK promoter. To delin-
eate a functional PPRE in the LGK promoter, we con-
structed an LGK promoter–luciferase reporter construct
that contained the 1448/127 region of the LGK pro-
moter and performed a transient transfection assay. The
LGK promoter was activated by fivefold when transfected
into Alexander cells with overexpression of PPAR- and
RXR- in the presence of their ligands. This result sug-
gested that functional PPRE is present in the LGK pro-
moter (Fig. 2). To localize the PPRE in the 1448/127
region, we prepared 5 deletion constructs and performed
deletion study. In this experiment, pRGL-238 and pRGL-
120 were still activated by PPAR-, but deletion down to
the 76 region of the LGK promoter resulted in loss of
PPAR- responsiveness. These results suggested that pu-
tative LGK-PPRE could be present between the 120 and
76 region. To narrow down the functional PPRE, we
prepared mutant promoter–reporter constructs pRGLt-
120/-77 and pRGLt-89/-63, where the 120/77 region and
89/63 region were removed from pRGL-238, respec-
tively. Of the two truncated promoters, pRGLt-120/-77 did
not respond to PPAR-, whereas pRGLt-89/-63 still re-
tained responsiveness, suggesting that PPRE could be
located in the 120/89 region. The consensus sequence
of PPRE was known to be DR1, a hexameric consensus
sequence (AGGTCA) in a direct repeat spaced by one
nucleotide (19). But there were three AGGTCA sequences
in the 120/89 region. Thus, we prepared three mutants
to further localize the PPRE. Substitution mutations were
introduced into putative AGGTCA sequences of minimal
rat LGK promoter reporter construct pRGL-238 and named
pRGL-238M1, pRGL-238M2, and pRGL-238M3, respec-
tively. Among these three mutants, pRGL-238M3 was acti-
vated by PPAR-, whereas pRGL-238M1 and pRGL-238M2
were not. These data indicate that the first two reverse
“AGGTCA” sequences constitute DR1. Thus, we could
define the 116/104 region containing the sequence of
GTCCCTGTGGCCT as LGK-PPRE, which is responsible
for the functional activation of the LGK promoter by
PPAR-.
Binding of the PPAR-/RXR- heterodimer to LGK-
PPRE. The binding of the PPAR-/RXR- heterodimer to
LGK-PPRE was analyzed by EMSA using in vitro translated
PPAR- and RXR-. As shown in Fig. 3A, the heterodimer
of PPAR- and RXR- could bind to RGL-120/-77 and
RGL-120/-77M3 probes. However, RGL-120/-77M1 and
RGL-120/-77M2 were not bound by the proteins. The
identity of the PPAR-/RXR- heterodimer bound to LGK-
PPRE was further confirmed by supershift assay using the
anti–PPAR- antibody, which could block the DNA bind-
ing of PPAR-. In addition, we confirmed the specificity of
the binding by competition assay (Fig. 3B). Fifty-molar
excess cold competitors were coincubated with a wild-
type probe. Wild competitor and RGL-120/-77M3 could
compete out the binding, but RGL-120/-77M1 and RGL-
120/-77M2 could not. These results demonstrated that the
LGK promoter could be activated by PPAR- through the
binding of the PPAR-/RXR- heterodimer to LGK-PPRE.
FIG. 1. LGK transcription was increased by troglitazone. Primary
hepatocytes were cultured for 48 h in the presence or absence of
troglitazone (20 mol/l) and 9-cis retinoic acid (1 mol/l). Total RNA
(20 g) was separated on 1% agarose gels and transferred onto a nylon
membrane. The membrane was hybridized with 32P-labeled GK and
-actin cDNA probes. The -actin gene was used as an internal control.
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DISCUSSION
Several hepatic genes that are involved in glycolysis,
glycogen synthesis, and lipogenesis are regulated by glu-
cose, and GK expression is essential to this process (1). In
type 2 diabetic subjects, hepatic glucose production is
increased and glycogen synthesis is decreased because of
insulin resistance and increased free fatty acid. PPAR-
agonists were known to increase peripheral insulin sensi-
tivity and increase glucose-sensing ability in pancreatic
-cells (11). They also decrease free fatty acid levels by
repartitioning the fat to adipocytes and hepatic glucose
production by decreasing gluconeogenic gene expression
and increasing GK expression in diabetic ZDF rats (20). It
has been a matter of debate whether the antidiabetic
effects of TZDs are due to the improved insulin sensitivity
or direct transcriptional activation of genes involved in
FIG. 2. The LGK promoter contained
functional PPRE. A: Structures of LGK
promoter luciferase reporter con-
structs. DNA sequences of the wild-type
and mutant versions of the promoter
element were shown to define the
PPRE. The hexameric consensus se-
quences are underlined with arrows,
and mutated nucleotides are shown. B:
Luciferase reporter constructs under
the control of the rat LGK promoter
spanning from 1448, 238, 120, or
76 to 127, respectively, were co-
transfected into Alexander cells with
(f) or without () the indicated PPAR-
/RXR- expression vector. C: Lucif-
erase reporter constructs under control
of the LGK minimal promoter or its
mutants were transfected into Alex-
ander cells with (f) or without () the
indicated PPAR-/RXR- expression
vector. The cells were incubated for
18 h after transfection in the presence
of appropriate ligands: 20 mol/l trogli-
tazone for PPAR- and 1 mol/l 9-cis
retinoic acid for RXR-. Normalized lu-
ciferase activities are shown as means 
SD of three independent experiments in
triplicate and are expressed as the fold
increase relative to the basal activity,
respectively, in the absence of the ex-
pression vectors and ligands.
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glucose homeostasis. However, the effects of PPAR- on
liver have been regarded as rather indirect, because the
ligand-induced decrease in free fatty acid levels preceded
that in glucose and the change of hepatic gene expressions
(20).
In the present study, we have identified a functional
PPRE in the rat LGK promoter. The LGK-PPRE was
localized within 116/104, which contained the se-
quence GTCCCTGTGGCCT, by promoter analysis per-
formed in Alexander cells. PPAR- heterodimerized with
RXR- could bind to LGK-PPRE and activate the LGK
transcription. Also, we observed the activation of LGK
gene expression by PPAR- in primary hepatocytes.
Through this study, we demonstrate that LGK is a direct
target of PPAR- in liver. Given that GK is controlling the
influx of glucose and accompanying glycolysis in the liver
and enables glucose to regulate the enzymes involved in
the major metabolic pathway of the liver, the activation of
LGK expression by PPAR- seems to have an important
role in improving systemic glucose homeostasis.
Recently, evidence supporting the direct action of
PPAR- on glucose homeostasis has been accumulating.
We reported that GLUT2 and GK are the direct targets of
PPAR- in pancreatic -cells. Here, we present the evi-
dence that LGK could be directly activated by PPAR-. It is
the first demonstration that LGK could be a direct target of
PPAR-, and the activation may contribute to improved
glucose homeostasis independent of the systemic effects
of PPAR-.
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